Skip to main content

Advertisement

Log in

Clinical Practice Guidelines for the Utilization of Positron Emission Tomography/Computed Tomography Imaging in Selected Oncologic Applications: Suggestions from a Provider Group

  • Editorial
  • Published:
Molecular Imaging and Biology Aims and scope Submit manuscript

Abstract

Purpose

Positron emission tomography, combined with computed tomography (PET/CT) has provided clinicians with useful information regarding the diagnosis, initial staging, restaging, and therapy monitoring of malignancies since the beginning of the current century. Our intent here is to identify the critical steps in clinical workups and follow-up, in the true outpatient clinical setting of a freestanding imaging center, for utilization of PET/CT in four different cancer types.

Methods

The four most common reasons for referrals to our facility were identified by reviewing two years of referral data. They were lung cancer (including solitary pulmonary nodule), lymphomas, breast cancer, and colorectal cancer. A review of published literature from 1996 and later was accepted as evidence of appropriateness for utilizing PET/CT in various clinical scenarios. In addition, a medical advisory board consisting of 15 referring physicians representing various specialties was established to provide practical advice regarding the appropriate use of PET/CT in clinical situations. National Comprehensive Cancer Network (NCCN) guidelines were also referenced to establish a baseline for clinical workups at various stages of disease.

Results

Several inconsistencies were identified among the three primary sources of information leading to the establishment of a standardized algorithm for each cancer type. NCCN data did not always agree with published literature, which was also often different from actual clinical practices of referring physicians. The most common inconsistencies included differing opinions from the referrers vs what was published in the NCCN guidelines, especially with regard to the utilization of PET/CT for applications not yet covered by insurance companies. After a reconciliation of the medical advisory board’s clinical practices and several published articles, a consensus was established by the medical advisory board for the use of PET/CT imaging for the four cancer types, enabling us to identify the appropriate timing of PET/CT utilization in patient work-ups.

Conclusions

A PET/CT-centric clinical practice decision tree algorithm can be established by assessing a variety of sources of information. Although published literature and NCCN guidelines offer validated guidance to appropriateness, and third party insurance payors have established their own appropriateness standards, our experience showed that inclusion of practical experience from referring physicians who frequently utilize PET/CT imaging provided additional, useful input.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Abbreviations

H&P:

history and physical

Tx:

treatment

Bilat Dx mammogram:

bilateral diagnostic mammogram

CXR:

chest x-ray

Chest CT:

computed tomography of chest

CBC:

complete blood count

Primary Bx:

biopsy of primary tumor site

SNBx:

biopsy of sentinel lymph node

PET/CT:

combined positron emission tomography and computed tomography scan

MRI:

magnetic resonance imaging

Rad Tx:

radiation therapy

Alk. Phos.:

alkaline phosphotase

Pt:

patient

SUV:

standard uptake value

BUN:

blood urea nitrogen

Creat:

creatinine

CT w/Cx:

computed tomography with contrast

Path Conf:

pathology confirmation

w/o:

without

CEA:

carcinoembryonic antigen

Abd:

abdomen

I.V.:

intravenous

Mgmt:

management

Y-90:

yttrium-90 isotope

Radio:

radiation therapy

Chemo:

chemotherapy

Mets::

metastasis (es)

Mo/Mos::

month/months

(+)/(−):

positive/negative

References

  1. Beyer T, Townsend DW, Brun T, et al. (2000) A combined PET/CT scanner for clinical oncology. J Nucl Med 41:1369–1379

    PubMed  CAS  Google Scholar 

  2. Jaroff, Leon, A Winning Combination. In: TIME; December 3, 2000

  3. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology, v.2.2006 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp?button=I+Agree#site

  4. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16:1160–1168

    Article  PubMed  CAS  Google Scholar 

  5. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology, v.2.2006 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp?button=I+Agree#site

  6. Schöder H, Larson S, Yeung H PET/CT in Oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 45:72S–81S, (suppl)

  7. Georgia Medicare News newsletter (2005) Cahaba Government Benefit Administrators, May

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ken Manning.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Manning, K., Tepfer, B., Goldklang, G. et al. Clinical Practice Guidelines for the Utilization of Positron Emission Tomography/Computed Tomography Imaging in Selected Oncologic Applications: Suggestions from a Provider Group. Mol Imaging Biol 9, 324–332 (2007). https://doi.org/10.1007/s11307-007-0106-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-007-0106-3

Key words

Navigation